Budde, Lihua E.
City Of Hope National Medical Center
4 papers on CoChatORCID 0000-0003-1464-5494
Most cited papers
- Verified
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 570
- Verified
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., et al. (2025) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 94
- Verified
Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study
Morschhauser, F., Bishton, M., Eyre, T. A., Bachy, E., Cartron, G., Ysebaert, L., Bobillo, S., Gutierrez, N. C., Budde, L. E., Fox, C. P., et al. (2021) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 46
- Verified
Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma
Li, C.-C., Bender, B., Yin, S., Li, Z., Zhang, C., Hernandez, G., Kwan, A., Sun, L., Adamkewicz, J. I., Wang, H., et al. (2019) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 14
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free